India, Sept. 15 -- The Hyderabad-based API manufacturer and CDMO, has quietly reached a milestone in its peptide manufacturing push, bringing the first of several planned production modules online at a purpose-built site. The launch follows a multimillion-dollar capital commitment and comes as the company works closely with an anchor customer on what's next. With demand for peptide-based drugs climbing across multiple therapeutic areas, the move offers an early signal of where Neuland is placing its next big bet.

Shares of Neuland Laboratories Ltd are trading at Rs. 22,940.00, down 2.55 percent on Tuesday. The stock touched the intraday high of Rs. 23,480.00 after opening at Rs. 23,430.00 before slipping to a low of Rs. 22,885.00. The c...